Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2
cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of
allopurinol. The safety of this treatment will also be studied.